Sign in to follow this  
Followers 0
Jeannie McClelland

Effect of bosentan on skin fibrosis in patients with systemic sclerosis: a prospective, open-label, non-comparative trial

1 post in this topic

Effect of bosentan on skin fibrosis in patients with systemic sclerosis: a prospective, open-label, non-comparative trial. In addition to the well-known effect of bosentan in prevention of digital ulcers, the results of this study demonstrate that bosentan may also be effective at reducing skin fibrosis in patients with SSc. Annegret Kuhn Rheumatology, April 5, 2010 (Also see: Skin Fibrosis)

This item was posted in the ISN Newsroom. Check the Newsroom every day for the latest scleroderma medical


Jeannie McClelland

(Retired) ISN Director of Support Services

(Retired) ISN Sclero Forums Manager

(Retired) ISN Blog Manager

(Retired) ISN Assistant News Guide

(Retired) ISN Artist

International Scleroderma Network

Share this post


Link to post
Share on other sites

Create an account or sign in to comment

You need to be a member in order to leave a comment

Create an account

Sign up for a new account in our community. It's easy!


Register a new account

Sign in

Already have an account? Sign in here.


Sign In Now
Sign in to follow this  
Followers 0